Report Detail
Global (United States, European Union and China) Glioblastoma Multiforme Therapeutics Market Research Report 2019-2025
- RnM3635435 |
- 30 July, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
In 2019, the market size of Glioblastoma Multiforme Therapeutics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Glioblastoma Multiforme Therapeutics.
This report studies the global market size of Glioblastoma Multiforme Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Glioblastoma Multiforme Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Arbor Pharmaceuticals
Bristol-Myers Squibb
Eisai
F. Hoffmann-La Roche
Merck
...
Market Segment by Product Type
Temozolomide
Bevacozumab
Carmustine
Market Segment by Application
Hospitals
Clinics
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Glioblastoma Multiforme Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Glioblastoma Multiforme Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Glioblastoma Multiforme Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Glioblastoma Multiforme Therapeutics Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Temozolomide
- 1.3.3 Bevacozumab
- 1.3.4 Carmustine
- 1.4 Market Segment by Application
- 1.4.1 Global Glioblastoma Multiforme Therapeutics Market Share by Application (2019-2025)
- 1.4.2 Hospitals
- 1.4.3 Clinics
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Glioblastoma Multiforme Therapeutics Market Size
- 2.1.1 Global Glioblastoma Multiforme Therapeutics Revenue 2014-2025
- 2.1.2 Global Glioblastoma Multiforme Therapeutics Sales 2014-2025
- 2.2 Glioblastoma Multiforme Therapeutics Growth Rate by Regions
- 2.2.1 Global Glioblastoma Multiforme Therapeutics Sales by Regions 2014-2019
- 2.2.2 Global Glioblastoma Multiforme Therapeutics Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Glioblastoma Multiforme Therapeutics Sales by Manufacturers
- 3.1.1 Glioblastoma Multiforme Therapeutics Sales by Manufacturers 2014-2019
- 3.1.2 Glioblastoma Multiforme Therapeutics Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Glioblastoma Multiforme Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Glioblastoma Multiforme Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Glioblastoma Multiforme Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.3 Glioblastoma Multiforme Therapeutics Price by Manufacturers
- 3.4 Key Manufacturers Glioblastoma Multiforme Therapeutics Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Glioblastoma Multiforme Therapeutics Market
- 3.6 Key Manufacturers Glioblastoma Multiforme Therapeutics Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Temozolomide Sales and Revenue (2014-2019)
- 4.1.2 Bevacozumab Sales and Revenue (2014-2019)
- 4.1.3 Carmustine Sales and Revenue (2014-2019)
- 4.2 Global Glioblastoma Multiforme Therapeutics Sales Market Share by Type
- 4.3 Global Glioblastoma Multiforme Therapeutics Revenue Market Share by Type
- 4.4 Glioblastoma Multiforme Therapeutics Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Glioblastoma Multiforme Therapeutics Sales by Application
6 United States
- 6.1 United States Glioblastoma Multiforme Therapeutics Breakdown Data by Company
- 6.2 United States Glioblastoma Multiforme Therapeutics Breakdown Data by Type
- 6.3 United States Glioblastoma Multiforme Therapeutics Breakdown Data by Application
7 European Union
- 7.1 European Union Glioblastoma Multiforme Therapeutics Breakdown Data by Company
- 7.2 European Union Glioblastoma Multiforme Therapeutics Breakdown Data by Type
- 7.3 European Union Glioblastoma Multiforme Therapeutics Breakdown Data by Application
8 China
- 8.1 China Glioblastoma Multiforme Therapeutics Breakdown Data by Company
- 8.2 China Glioblastoma Multiforme Therapeutics Breakdown Data by Type
- 8.3 China Glioblastoma Multiforme Therapeutics Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Glioblastoma Multiforme Therapeutics Breakdown Data by Company
- 9.2 Rest of World Glioblastoma Multiforme Therapeutics Breakdown Data by Type
- 9.3 Rest of World Glioblastoma Multiforme Therapeutics Breakdown Data by Application
- 9.4 Rest of World Glioblastoma Multiforme Therapeutics Breakdown Data by Countries
- 9.4.1 Rest of World Glioblastoma Multiforme Therapeutics Sales by Countries
- 9.4.2 Rest of World Glioblastoma Multiforme Therapeutics Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Arbor Pharmaceuticals
- 10.1.1 Arbor Pharmaceuticals Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Glioblastoma Multiforme Therapeutics
- 10.1.4 Glioblastoma Multiforme Therapeutics Product Introduction
- 10.1.5 Arbor Pharmaceuticals Recent Development
- 10.2 Bristol-Myers Squibb
- 10.2.1 Bristol-Myers Squibb Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Glioblastoma Multiforme Therapeutics
- 10.2.4 Glioblastoma Multiforme Therapeutics Product Introduction
- 10.2.5 Bristol-Myers Squibb Recent Development
- 10.3 Eisai
- 10.3.1 Eisai Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Glioblastoma Multiforme Therapeutics
- 10.3.4 Glioblastoma Multiforme Therapeutics Product Introduction
- 10.3.5 Eisai Recent Development
- 10.4 F. Hoffmann-La Roche
- 10.4.1 F. Hoffmann-La Roche Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Glioblastoma Multiforme Therapeutics
- 10.4.4 Glioblastoma Multiforme Therapeutics Product Introduction
- 10.4.5 F. Hoffmann-La Roche Recent Development
- 10.5 Merck
- 10.5.1 Merck Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Glioblastoma Multiforme Therapeutics
- 10.5.4 Glioblastoma Multiforme Therapeutics Product Introduction
- 10.5.5 Merck Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Glioblastoma Multiforme Therapeutics Sales Channels
- 11.2.2 Glioblastoma Multiforme Therapeutics Distributors
- 11.3 Glioblastoma Multiforme Therapeutics Customers
12 Market Forecast
- 12.1 Global Glioblastoma Multiforme Therapeutics Sales and Revenue Forecast 2019-2025
- 12.2 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Type
- 12.3 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Application
- 12.4 Glioblastoma Multiforme Therapeutics Forecast by Regions
- 12.4.1 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Regions 2019-2025
- 12.4.2 Global Glioblastoma Multiforme Therapeutics Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Glioblastoma Multiforme Therapeutics. Industry analysis & Market Report on Glioblastoma Multiforme Therapeutics is a syndicated market report, published as Global (United States, European Union and China) Glioblastoma Multiforme Therapeutics Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Glioblastoma Multiforme Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
